Share Price and Basic Stock Data
Last Updated: January 3, 2026, 10:46 am
| PEG Ratio | 6.73 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Procter & Gamble Hygiene and Health Care Ltd operates in the personal care industry with a current price of ₹12,888 and a market capitalization of ₹41,847 Cr. The company reported steady revenue growth, with sales increasing from ₹3,901 Cr in FY 2022 to ₹4,206 Cr in FY 2024. The quarterly sales figures show fluctuations, with a peak of ₹1,248 Cr in Dec 2024, indicating resilience in consumer demand despite economic challenges. The trailing twelve months (TTM) revenue stood at ₹4,326 Cr, showcasing a robust recovery trajectory. The company’s sales efficiency, reflected in the revenue from operations per share of ₹1,039.56 for Mar 2025, demonstrates its ability to generate substantial sales relative to its share base. However, the revenue growth must be viewed in the context of competitive pressures within the personal care sector, which typically sees varying demand dynamics influenced by consumer preferences and economic conditions.
Profitability and Efficiency Metrics
Procter & Gamble Hygiene and Health Care Ltd exhibited strong profitability metrics, with a reported net profit of ₹827 Cr for FY 2025 and an impressive return on equity (ROE) of 75.7%. The operating profit margin (OPM) stood at 25%, indicative of effective cost management and pricing strategies. The quarterly operating profit peaked at ₹371 Cr in Dec 2024, reflecting the company’s ability to maintain margins in a competitive environment. The interest coverage ratio (ICR) was notably high at 38.18x, suggesting that the company can comfortably meet its interest obligations. Efficiency metrics such as the cash conversion cycle of -138 days highlight operational effectiveness, allowing the company to convert investments in inventory into cash flow rapidly. However, the fluctuating OPM, which saw a low of 13% in Jun 2024, raises concerns about potential vulnerabilities in maintaining profitability during challenging periods.
Balance Sheet Strength and Financial Ratios
Procter & Gamble Hygiene and Health Care Ltd’s balance sheet demonstrates notable strength, with total liabilities standing at ₹1,755 Cr against total assets of ₹1,755 Cr. The company maintains minimal borrowings of just ₹2 Cr, underscoring a conservative capital structure and low financial risk. Reserves reported at ₹899 Cr provide a cushion for future investments and operational flexibility. The price-to-book value ratio (P/BV) stood at a high 69.63x, indicating market confidence but also suggesting that the stock may be overvalued compared to its book value. Moreover, the return on capital employed (ROCE) of 104% reinforces the company’s capability to generate profitable returns on its capital investments. The current ratio of 1.23 indicates adequate liquidity to cover short-term obligations, although a declining trend in working capital days could signal tightening operational efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Procter & Gamble Hygiene and Health Care Ltd reflects strong promoter confidence, with promoters holding 70.64% of the company. This level of ownership may instill investor confidence regarding long-term strategic direction. Foreign institutional investors (FIIs) accounted for 1.11% of the shareholding, while domestic institutional investors (DIIs) held 16.05%, indicating a balanced institutional interest. The number of shareholders rose to 49,997, demonstrating increasing retail investor participation. However, the relatively low FII participation suggests potential barriers to broader market acceptance. The dividend payout ratio for Mar 2025 stood at 104.53%, highlighting the company’s commitment to returning capital to shareholders, though this high payout could raise concerns about future reinvestment capabilities. Overall, the shareholding structure signals strength but may also reflect underlying challenges in attracting external investment.
Outlook, Risks, and Final Insight
Procter & Gamble Hygiene and Health Care Ltd’s outlook appears cautiously optimistic given its strong profitability metrics and solid balance sheet. However, risks remain, including fluctuating operating margins and the potential impact of rising competition in the personal care sector. The company must navigate consumer behavior shifts and economic pressures that could affect sales. Additionally, while the high dividend payout ratio signals shareholder value, it may limit reinvestment in growth initiatives. Strategic focus on innovation and cost management will be crucial for sustaining growth. Potential scenarios include maintaining current profitability levels or facing margin pressures if economic conditions deteriorate. The company’s ability to adapt to market changes while leveraging its operational strengths will define its future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 9,520 Cr. | 293 | 334/190 | 76.5 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 42.4 Cr. | 25.5 | 37.0/23.3 | 83.2 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 115 Cr. | 120 | 149/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 612 Cr. | 403 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 10,440 Cr. | 284 | 423/268 | 28.5 | 55.8 | 1.23 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 70,624.43 Cr | 1,914.00 | 59.48 | 112.70 | 0.75% | 29.21% | 23.91% | 4.94 |
All Competitor Stocks of Procter & Gamble Hygiene and Health Care Ltd
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,045 | 1,137 | 883 | 853 | 1,138 | 1,133 | 1,002 | 932 | 1,135 | 1,248 | 992 | 937 | 1,150 |
| Expenses | 831 | 847 | 734 | 638 | 853 | 824 | 745 | 813 | 845 | 877 | 782 | 671 | 865 |
| Operating Profit | 214 | 290 | 149 | 215 | 285 | 310 | 257 | 118 | 290 | 371 | 210 | 266 | 285 |
| OPM % | 20% | 26% | 17% | 25% | 25% | 27% | 26% | 13% | 26% | 30% | 21% | 28% | 25% |
| Other Income | 7 | 9 | 14 | 10 | 16 | 16 | 14 | 7 | 8 | 10 | 19 | 8 | 10 |
| Interest | 1 | 4 | 4 | 3 | 2 | 3 | 22 | -0 | 2 | 7 | 6 | 0 | 4 |
| Depreciation | 14 | 14 | 15 | 15 | 14 | 14 | 15 | 13 | 12 | 10 | 10 | 9 | 9 |
| Profit before tax | 206 | 282 | 146 | 207 | 284 | 309 | 234 | 112 | 285 | 364 | 213 | 265 | 282 |
| Tax % | 25% | 26% | -13% | 27% | 26% | 26% | 34% | 28% | 26% | 26% | 27% | 27% | 26% |
| Net Profit | 154 | 207 | 165 | 151 | 211 | 229 | 154 | 81 | 212 | 269 | 156 | 192 | 210 |
| EPS in Rs | 47.57 | 63.91 | 50.84 | 46.59 | 64.91 | 70.52 | 47.56 | 24.97 | 65.28 | 82.74 | 48.09 | 59.17 | 64.65 |
Last Updated: January 2, 2026, 5:36 pm
Below is a detailed analysis of the quarterly data for Procter & Gamble Hygiene and Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,150.00 Cr.. The value appears strong and on an upward trend. It has increased from 937.00 Cr. (Jun 2025) to 1,150.00 Cr., marking an increase of 213.00 Cr..
- For Expenses, as of Sep 2025, the value is 865.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 671.00 Cr. (Jun 2025) to 865.00 Cr., marking an increase of 194.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 285.00 Cr.. The value appears strong and on an upward trend. It has increased from 266.00 Cr. (Jun 2025) to 285.00 Cr., marking an increase of 19.00 Cr..
- For OPM %, as of Sep 2025, the value is 25.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Jun 2025) to 25.00%, marking a decrease of 3.00%.
- For Other Income, as of Sep 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Sep 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Jun 2025) to 4.00 Cr., marking an increase of 4.00 Cr..
- For Depreciation, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 9.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 282.00 Cr.. The value appears strong and on an upward trend. It has increased from 265.00 Cr. (Jun 2025) to 282.00 Cr., marking an increase of 17.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Jun 2025) to 26.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Jun 2025) to 210.00 Cr., marking an increase of 18.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 64.65. The value appears strong and on an upward trend. It has increased from 59.17 (Jun 2025) to 64.65, marking an increase of 5.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:45 am
| Metric | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 9m | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,051 | 2,334 | 2,275 | 2,320 | 2,455 | 2,947 | 3,002 | 3,574 | 3,901 | 3,918 | 4,206 | 3,374 | 4,326 |
| Expenses | 1,628 | 1,838 | 1,667 | 1,646 | 1,834 | 2,329 | 2,396 | 2,688 | 3,069 | 3,048 | 3,230 | 2,503 | 3,195 |
| Operating Profit | 423 | 495 | 608 | 675 | 622 | 618 | 606 | 886 | 832 | 869 | 976 | 871 | 1,132 |
| OPM % | 21% | 21% | 27% | 29% | 25% | 21% | 20% | 25% | 21% | 22% | 23% | 26% | 26% |
| Other Income | 78 | 64 | 85 | 67 | 18 | 45 | 42 | 38 | 23 | 40 | 47 | 37 | 46 |
| Interest | 5 | 6 | 6 | 10 | 5 | 5 | 6 | 6 | 11 | 11 | 27 | 14 | 16 |
| Depreciation | 35 | 53 | 52 | 60 | 52 | 50 | 48 | 48 | 53 | 58 | 56 | 32 | 39 |
| Profit before tax | 460 | 501 | 636 | 672 | 582 | 607 | 594 | 870 | 790 | 839 | 939 | 862 | 1,123 |
| Tax % | 34% | 31% | 34% | 36% | 36% | 31% | 27% | 25% | 27% | 19% | 28% | 26% | |
| Net Profit | 302 | 346 | 422 | 433 | 375 | 419 | 433 | 652 | 576 | 678 | 675 | 637 | 827 |
| EPS in Rs | 93.04 | 106.63 | 130.16 | 133.31 | 115.40 | 129.12 | 133.42 | 200.79 | 177.37 | 208.91 | 207.95 | 196.11 | 254.65 |
| Dividend Payout % | 30% | 28% | 28% | 292% | 35% | 68% | 79% | 157% | 90% | 89% | 123% | 89% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 3% |
| 3 Years: | -2% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | -1% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 52% |
| 5 Years: | 68% |
| 3 Years: | 79% |
| Last Year: | 76% |
Last Updated: September 4, 2025, 9:30 pm
Balance Sheet
Last Updated: December 4, 2025, 12:51 am
| Month | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 |
| Reserves | 970 | 1,196 | 1,619 | 494 | 773 | 877 | 1,125 | 682 | 705 | 914 | 742 | 705 | 899 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 4 | 3 | 2 | 2 |
| Other Liabilities | 505 | 719 | 515 | 634 | 620 | 708 | 671 | 915 | 940 | 1,187 | 1,081 | 1,015 | 1,200 |
| Total Liabilities | 1,508 | 1,948 | 2,166 | 1,160 | 1,425 | 1,617 | 1,828 | 1,633 | 1,683 | 2,137 | 1,859 | 1,755 | 2,133 |
| Fixed Assets | 240 | 309 | 317 | 286 | 250 | 234 | 206 | 184 | 164 | 170 | 139 | 131 | 166 |
| CWIP | 98 | 39 | 35 | 41 | 21 | 15 | 22 | 38 | 44 | 23 | 28 | 41 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,170 | 1,600 | 1,814 | 834 | 1,154 | 1,368 | 1,600 | 1,411 | 1,475 | 1,945 | 1,692 | 1,583 | 1,953 |
| Total Assets | 1,508 | 1,948 | 2,166 | 1,160 | 1,425 | 1,617 | 1,828 | 1,633 | 1,683 | 2,137 | 1,859 | 1,755 | 2,133 |
Below is a detailed analysis of the balance sheet data for Procter & Gamble Hygiene and Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 32.00 Cr..
- For Reserves, as of Sep 2025, the value is 899.00 Cr.. The value appears strong and on an upward trend. It has increased from 705.00 Cr. (Mar 2025) to 899.00 Cr., marking an increase of 194.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,200.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,015.00 Cr. (Mar 2025) to 1,200.00 Cr., marking an increase of 185.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,133.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,755.00 Cr. (Mar 2025) to 2,133.00 Cr., marking an increase of 378.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 166.00 Cr.. The value appears strong and on an upward trend. It has increased from 131.00 Cr. (Mar 2025) to 166.00 Cr., marking an increase of 35.00 Cr..
- For CWIP, as of Sep 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 27.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,953.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,583.00 Cr. (Mar 2025) to 1,953.00 Cr., marking an increase of 370.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,133.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,755.00 Cr. (Mar 2025) to 2,133.00 Cr., marking an increase of 378.00 Cr..
Notably, the Reserves (899.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 9m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 423.00 | 495.00 | 608.00 | 675.00 | 622.00 | 618.00 | 606.00 | 883.00 | 827.00 | 865.00 | 973.00 | 871.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 15 | 18 | 24 | 21 | 22 | 22 | 20 | 15 | 18 | 20 | 21 | 33 |
| Inventory Days | 53 | 47 | 53 | 71 | 48 | 60 | 68 | 78 | 55 | 48 | 51 | 64 |
| Days Payable | 103 | 148 | 134 | 145 | 156 | 162 | 175 | 237 | 183 | 213 | 193 | 235 |
| Cash Conversion Cycle | -35 | -83 | -57 | -53 | -87 | -79 | -87 | -144 | -110 | -145 | -121 | -138 |
| Working Capital Days | 43 | 4 | 8 | -15 | -23 | -12 | -21 | -39 | -34 | -53 | -32 | -31 |
| ROCE % | 52% | 46% | 45% | 64% | 89% | 73% | 58% | 94% | 110% | 101% | 112% | 104% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Focused Fund | 900,000 | 2.68 | 1148.04 | N/A | N/A | N/A |
| ICICI Prudential Large Cap Fund | 532,050 | 0.87 | 678.68 | N/A | N/A | N/A |
| SBI Equity Hybrid Fund | 430,000 | 0.66 | 548.51 | 430,000 | 2025-04-22 15:16:47 | 0% |
| SBI Midcap Fund | 280,000 | 1.53 | 357.17 | N/A | N/A | N/A |
| Sundaram Mid Cap Fund | 95,691 | 0.91 | 122.06 | 91,606 | 2025-12-15 04:26:01 | 4.46% |
| Franklin India Mid Cap Fund | 88,662 | 0.88 | 113.1 | N/A | N/A | N/A |
| Aditya Birla Sun Life MNC Fund | 69,490 | 2.44 | 88.64 | N/A | N/A | N/A |
| UTI MNC Fund | 49,185 | 2.18 | 62.74 | 38,010 | 2025-12-08 02:04:55 | 29.4% |
| Aditya Birla Sun Life Consumption Fund | 38,899 | 0.76 | 49.62 | N/A | N/A | N/A |
| Sundaram Large and Mid Cap Fund | 34,236 | 0.62 | 43.67 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 196.11 | 207.95 | 208.91 | 177.37 | 200.79 |
| Diluted EPS (Rs.) | 196.11 | 207.95 | 208.91 | 177.37 | 200.79 |
| Cash EPS (Rs.) | 205.96 | 225.36 | 226.89 | 193.66 | 215.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 227.04 | 238.71 | 291.44 | 227.22 | 220.05 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 227.04 | 238.71 | 291.44 | 227.22 | 220.05 |
| Dividend / Share (Rs.) | 175.00 | 255.00 | 185.00 | 160.00 | 315.00 |
| Revenue From Operations / Share (Rs.) | 1039.56 | 1295.66 | 1206.99 | 1201.76 | 1101.09 |
| PBDIT / Share (Rs.) | 279.85 | 315.00 | 280.10 | 263.16 | 284.55 |
| PBIT / Share (Rs.) | 270.01 | 297.59 | 262.12 | 246.87 | 269.87 |
| PBT / Share (Rs.) | 265.61 | 289.34 | 258.62 | 243.42 | 267.99 |
| Net Profit / Share (Rs.) | 196.12 | 207.95 | 208.91 | 177.37 | 200.80 |
| PBDIT Margin (%) | 26.92 | 24.31 | 23.20 | 21.89 | 25.84 |
| PBIT Margin (%) | 25.97 | 22.96 | 21.71 | 20.54 | 24.50 |
| PBT Margin (%) | 25.54 | 22.33 | 21.42 | 20.25 | 24.33 |
| Net Profit Margin (%) | 18.86 | 16.05 | 17.30 | 14.75 | 18.23 |
| Return on Networth / Equity (%) | 86.37 | 87.11 | 71.68 | 78.06 | 91.25 |
| Return on Capital Employeed (%) | 102.66 | 110.03 | 80.85 | 97.31 | 109.87 |
| Return On Assets (%) | 36.27 | 36.31 | 31.72 | 34.24 | 39.92 |
| Asset Turnover Ratio (%) | 1.87 | 2.11 | 2.05 | 2.35 | 2.07 |
| Current Ratio (X) | 1.23 | 1.22 | 1.38 | 1.32 | 1.34 |
| Quick Ratio (X) | 0.98 | 0.99 | 1.18 | 1.05 | 1.04 |
| Inventory Turnover Ratio (X) | 15.10 | 3.47 | 3.74 | 5.22 | 4.97 |
| Dividend Payout Ratio (NP) (%) | 104.53 | 127.43 | 69.40 | 98.66 | 169.32 |
| Dividend Payout Ratio (CP) (%) | 99.53 | 117.59 | 63.90 | 90.36 | 157.79 |
| Earning Retention Ratio (%) | -4.53 | -27.43 | 30.60 | 1.34 | -69.32 |
| Cash Earning Retention Ratio (%) | 0.47 | -17.59 | 36.10 | 9.64 | -57.79 |
| Interest Coverage Ratio (X) | 63.52 | 38.18 | 79.90 | 76.34 | 151.17 |
| Interest Coverage Ratio (Post Tax) (X) | 45.52 | 26.21 | 60.59 | 52.45 | 107.68 |
| Enterprise Value (Cr.) | 43676.26 | 53361.78 | 45454.09 | 42869.00 | 42606.67 |
| EV / Net Operating Revenue (X) | 12.94 | 12.69 | 11.60 | 10.99 | 11.92 |
| EV / EBITDA (X) | 48.08 | 52.19 | 49.99 | 50.19 | 46.13 |
| MarketCap / Net Operating Revenue (X) | 13.09 | 12.83 | 11.85 | 11.15 | 12.11 |
| Retention Ratios (%) | -4.53 | -27.43 | 30.59 | 1.33 | -69.32 |
| Price / BV (X) | 59.92 | 69.63 | 49.08 | 58.99 | 60.58 |
| Price / Net Operating Revenue (X) | 13.09 | 12.83 | 11.85 | 11.15 | 12.11 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Procter & Gamble Hygiene and Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Jun 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 196.11. This value is within the healthy range. It has decreased from 207.95 (Jun 24) to 196.11, marking a decrease of 11.84.
- For Diluted EPS (Rs.), as of Mar 25, the value is 196.11. This value is within the healthy range. It has decreased from 207.95 (Jun 24) to 196.11, marking a decrease of 11.84.
- For Cash EPS (Rs.), as of Mar 25, the value is 205.96. This value is within the healthy range. It has decreased from 225.36 (Jun 24) to 205.96, marking a decrease of 19.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 227.04. It has decreased from 238.71 (Jun 24) to 227.04, marking a decrease of 11.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 227.04. It has decreased from 238.71 (Jun 24) to 227.04, marking a decrease of 11.67.
- For Dividend / Share (Rs.), as of Mar 25, the value is 175.00. This value exceeds the healthy maximum of 3. It has decreased from 255.00 (Jun 24) to 175.00, marking a decrease of 80.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,039.56. It has decreased from 1,295.66 (Jun 24) to 1,039.56, marking a decrease of 256.10.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 279.85. This value is within the healthy range. It has decreased from 315.00 (Jun 24) to 279.85, marking a decrease of 35.15.
- For PBIT / Share (Rs.), as of Mar 25, the value is 270.01. This value is within the healthy range. It has decreased from 297.59 (Jun 24) to 270.01, marking a decrease of 27.58.
- For PBT / Share (Rs.), as of Mar 25, the value is 265.61. This value is within the healthy range. It has decreased from 289.34 (Jun 24) to 265.61, marking a decrease of 23.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 196.12. This value is within the healthy range. It has decreased from 207.95 (Jun 24) to 196.12, marking a decrease of 11.83.
- For PBDIT Margin (%), as of Mar 25, the value is 26.92. This value is within the healthy range. It has increased from 24.31 (Jun 24) to 26.92, marking an increase of 2.61.
- For PBIT Margin (%), as of Mar 25, the value is 25.97. This value exceeds the healthy maximum of 20. It has increased from 22.96 (Jun 24) to 25.97, marking an increase of 3.01.
- For PBT Margin (%), as of Mar 25, the value is 25.54. This value is within the healthy range. It has increased from 22.33 (Jun 24) to 25.54, marking an increase of 3.21.
- For Net Profit Margin (%), as of Mar 25, the value is 18.86. This value exceeds the healthy maximum of 10. It has increased from 16.05 (Jun 24) to 18.86, marking an increase of 2.81.
- For Return on Networth / Equity (%), as of Mar 25, the value is 86.37. This value is within the healthy range. It has decreased from 87.11 (Jun 24) to 86.37, marking a decrease of 0.74.
- For Return on Capital Employeed (%), as of Mar 25, the value is 102.66. This value is within the healthy range. It has decreased from 110.03 (Jun 24) to 102.66, marking a decrease of 7.37.
- For Return On Assets (%), as of Mar 25, the value is 36.27. This value is within the healthy range. It has decreased from 36.31 (Jun 24) to 36.27, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.87. It has decreased from 2.11 (Jun 24) to 1.87, marking a decrease of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 1.5. It has increased from 1.22 (Jun 24) to 1.23, marking an increase of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has decreased from 0.99 (Jun 24) to 0.98, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 15.10. This value exceeds the healthy maximum of 8. It has increased from 3.47 (Jun 24) to 15.10, marking an increase of 11.63.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 104.53. This value exceeds the healthy maximum of 50. It has decreased from 127.43 (Jun 24) to 104.53, marking a decrease of 22.90.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 99.53. This value exceeds the healthy maximum of 50. It has decreased from 117.59 (Jun 24) to 99.53, marking a decrease of 18.06.
- For Earning Retention Ratio (%), as of Mar 25, the value is -4.53. This value is below the healthy minimum of 40. It has increased from -27.43 (Jun 24) to -4.53, marking an increase of 22.90.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.47. This value is below the healthy minimum of 40. It has increased from -17.59 (Jun 24) to 0.47, marking an increase of 18.06.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 63.52. This value is within the healthy range. It has increased from 38.18 (Jun 24) to 63.52, marking an increase of 25.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 45.52. This value is within the healthy range. It has increased from 26.21 (Jun 24) to 45.52, marking an increase of 19.31.
- For Enterprise Value (Cr.), as of Mar 25, the value is 43,676.26. It has decreased from 53,361.78 (Jun 24) to 43,676.26, marking a decrease of 9,685.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 12.94. This value exceeds the healthy maximum of 3. It has increased from 12.69 (Jun 24) to 12.94, marking an increase of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 48.08. This value exceeds the healthy maximum of 15. It has decreased from 52.19 (Jun 24) to 48.08, marking a decrease of 4.11.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.09. This value exceeds the healthy maximum of 3. It has increased from 12.83 (Jun 24) to 13.09, marking an increase of 0.26.
- For Retention Ratios (%), as of Mar 25, the value is -4.53. This value is below the healthy minimum of 30. It has increased from -27.43 (Jun 24) to -4.53, marking an increase of 22.90.
- For Price / BV (X), as of Mar 25, the value is 59.92. This value exceeds the healthy maximum of 3. It has decreased from 69.63 (Jun 24) to 59.92, marking a decrease of 9.71.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.09. This value exceeds the healthy maximum of 3. It has increased from 12.83 (Jun 24) to 13.09, marking an increase of 0.26.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Jun 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Procter & Gamble Hygiene and Health Care Ltd:
- Net Profit Margin: 18.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 102.66% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 86.37% (Industry Average ROE: 23.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 45.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.98
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 50.5 (Industry average Stock P/E: 59.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | P & G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400099 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chittranjan Dua | Chairman & Ind.Director |
| Mr. Kumar Venkatasubramanian | Managing Director |
| Mr. Ghanashyam Hegde | Executive Director |
| Mr. Pramod Agarwal | Non Executive Director |
| Mr. Gagan Sawhney | Non Executive Director |
| Ms. Sonali Dhawan | Non Executive Director |
| Mr. Krishnamurthy Iyer | Independent Director |
| Mr. Gurcharan Das | Independent Director |
| Dr. Ashima Goyal | Independent Director |
FAQ
What is the intrinsic value of Procter & Gamble Hygiene and Health Care Ltd?
Procter & Gamble Hygiene and Health Care Ltd's intrinsic value (as of 03 January 2026) is ₹8852.75 which is 31.13% lower the current market price of ₹12,854.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹41,725 Cr. market cap, FY2025-2026 high/low of ₹15,100/12,106, reserves of ₹899 Cr, and liabilities of ₹2,133 Cr.
What is the Market Cap of Procter & Gamble Hygiene and Health Care Ltd?
The Market Cap of Procter & Gamble Hygiene and Health Care Ltd is 41,725 Cr..
What is the current Stock Price of Procter & Gamble Hygiene and Health Care Ltd as on 03 January 2026?
The current stock price of Procter & Gamble Hygiene and Health Care Ltd as on 03 January 2026 is ₹12,854.
What is the High / Low of Procter & Gamble Hygiene and Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Procter & Gamble Hygiene and Health Care Ltd stocks is ₹15,100/12,106.
What is the Stock P/E of Procter & Gamble Hygiene and Health Care Ltd?
The Stock P/E of Procter & Gamble Hygiene and Health Care Ltd is 50.5.
What is the Book Value of Procter & Gamble Hygiene and Health Care Ltd?
The Book Value of Procter & Gamble Hygiene and Health Care Ltd is 287.
What is the Dividend Yield of Procter & Gamble Hygiene and Health Care Ltd?
The Dividend Yield of Procter & Gamble Hygiene and Health Care Ltd is 0.86 %.
What is the ROCE of Procter & Gamble Hygiene and Health Care Ltd?
The ROCE of Procter & Gamble Hygiene and Health Care Ltd is 104 %.
What is the ROE of Procter & Gamble Hygiene and Health Care Ltd?
The ROE of Procter & Gamble Hygiene and Health Care Ltd is 75.7 %.
What is the Face Value of Procter & Gamble Hygiene and Health Care Ltd?
The Face Value of Procter & Gamble Hygiene and Health Care Ltd is 10.0.